MannKind Corporation - Common Stock (MNKD)
Healthcare › Pharmaceutical Preparations
Price History
Feb 9, 2026 — Mar 31, 2026Investment Snapshot
- P/E of 21.9 — elevated valuation multiple
- Piotroski F-Score 2/9 — signs of financial weakness
- Strong ROE of 31.7% with 10.9% net margin
- Revenue growing at 22% annually
MannKind Corporation - Common Stock (MNKD) is a Healthcare company operating in Pharmaceutical Preparations, listed on the NASDAQ , with a market capitalisation of $730 million . Key value metrics: P/E ratio 21.9, Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
MannKind Corporation - Common Stock — Fundamental Analysis Summary
MannKind Corporation - Common Stock (MNKD) trades at a trailing P/E of 21.9x — 14% below the Healthcare sector average of 25.3x.
On financial health, MNKD shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and strong return on equity of 31.7% (sector average: -19.8%).
StockPik's composite Value Score for MNKD is 52/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
MNKD reports a high gross margin of 94.8% (sector average: 33.5%) and a solid operating margin of 19.3%.
MNKD shows revenue growing at 22% year-over-year, with earnings declining at 79%.